Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 527

1.

[Study on the value assessment of various screening programs regarding cervical cancer screening strategy in the rural areas of China].

Li LY, Qiao ZQ, Zhang MF, Yang JP, Bao YP, An YT, Lei J, Xiong NH, Yu XH, Zhang X, Pan QJ, Qiao YL.

Zhonghua Liu Xing Bing Xue Za Zhi. 2007 Oct;28(10):964-7. Chinese.

PMID:
18399140
2.

[Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].

Qian DY, Cen JM, Wang D, Zeng RH, Lin AH, Shu YH, Hong DH, Huang ZH.

Zhonghua Fu Chan Ke Za Zhi. 2006 Jan;41(1):34-7. Chinese.

PMID:
16635326
3.

Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) study.

Sarian LO, Derchain SF, Naud P, Roteli-Martins C, Longatto-Filho A, Tatti S, Branca M, Erzen M, Serpa-Hammes L, Matos J, Gontijo R, Bragança JF, Lima TP, Maeda MY, Lörincz A, Dores GB, Costa S, Syrjänen S, Syrjänen K.

J Med Screen. 2005;12(3):142-9.

PMID:
16156945
4.

Screening of cervical neoplasia in HIV-infected women in India.

Joshi S, Sankaranarayanan R, Muwonge R, Kulkarni V, Somanathan T, Divate U.

AIDS. 2013 Feb 20;27(4):607-15. doi: 10.1097/QAD.0b013e32835b1041.

PMID:
23079814
5.

Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.

Luyten A, Scherbring S, Reinecke-Lüthge A, Braun BE, Pietralla M, Theiler K, Petry KU.

J Clin Virol. 2009 Nov;46 Suppl 3:S5-10. doi: 10.1016/S1386-6532(09)70294-X.

PMID:
20129072
6.

Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India.

Shastri SS, Dinshaw K, Amin G, Goswami S, Patil S, Chinoy R, Kane S, Kelkar R, Muwonge R, Mahé C, Ajit D, Sankaranarayanan R.

Bull World Health Organ. 2005 Mar;83(3):186-94.

7.

Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study.

Syrjänen K, Naud P, Derchain S, Roteli-Martins C, Longatto-Filho A, Tatti S, Branca M, Erzen M, Hammes LS, Matos J, Gontijo R, Sarian L, Braganca J, Arlindo FC, Maeda MY, Lörincz A, Dores GB, Costa S, Syrjänen S.

Anticancer Res. 2005 Sep-Oct;25(5):3469-80.

9.

[Evaluation of gene chip technology for high risk type human papillomavirus in cervical cancer screening].

Li RZ, Shi JF, Zhou QZ, Wu RF, Li N, Wu LN, Zhou YQ, Wang Q, Liu ZH, Liu B, Qiao YL.

Zhonghua Yi Xue Za Zhi. 2006 Feb 7;86(5):307-11. Chinese.

PMID:
16677522
10.

Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J.

J Natl Cancer Inst. 2009 Jan 21;101(2):88-99. doi: 10.1093/jnci/djn444.

11.

[Evaluation on the visual inspection with Lugol's iodine in cervical cancer screening program].

Li N, Ma CP, Sun LX, Zhang YZ, Shao SL, Xing JX, Bao YP, Huang RD, He LJ, Qiao YL.

Zhonghua Liu Xing Bing Xue Za Zhi. 2006 Jan;27(1):15-8. Chinese.

PMID:
16737565
12.

Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.

Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, Dalla Palma P, Del Mistro A, Folicaldi S, Gillio-Tos A, Nardo G, Naldoni C, Schincaglia P, Zorzi M, Confortini M, Cuzick J; New Technologies for Cervical Cancer Working Group..

J Natl Cancer Inst. 2006 Jun 7;98(11):765-74.

13.
14.

Screening for cervical cancer: new alternatives and research.

Lörincz AT.

Salud Publica Mex. 2003;45 Suppl 3:S376-87. Review.

PMID:
14746031
15.

Analysis of the effectiveness of visual inspection with acetic acid/Lugol's iodine in one-time and annual follow-up screening in rural China.

Li R, Lewkowitz AK, Zhao FH, Zhou Q, Hu SY, Qiu H, Zhang Y, Jiang HW, Zhang JS, Li M, Tong SM, Zhang QY, Qiao YL.

Arch Gynecol Obstet. 2012 Jun;285(6):1627-32. doi: 10.1007/s00404-011-2203-4.

PMID:
22222723
16.

The Mexican Cervical Cancer Screening Trial: self-sampling for human papillomavirus with unaided visual inspection as a secondary screen.

Belinson JL, Pretorius RG, Enerson C, Garcia F, Cruz EP, Belinson SE, Yeverino García E, Brainard J.

Int J Gynecol Cancer. 2009 Jan;19(1):27-32. doi: 10.1111/IGC.0b013e318197f479.

PMID:
19258937
17.
18.

Screening for cervical cancer in high-risk populations: DNA pap test or Hybrid Capture II test alone?

Miranda Pereira SM, Castelo A, Makabe S, Utagawa ML, Di Loreto C, Sakamoto Maeda MY, Marques JA, Santoro CL, Filho AL, Das Dores GB.

Int J Gynecol Pathol. 2006 Jan;25(1):38-41.

PMID:
16306782
19.

[Use of high-risk human papillomavirus DNA testing to deal with atypical squamous cells undetermined significance and low squamous intraepithelial lesion].

Guo YL, You K, Geng L, Zhang XW, Shen XY, Yao YJ, Fan XH.

Beijing Da Xue Xue Bao. 2006 Oct 18;38(5):480-2. Chinese.

20.
Items per page

Supplemental Content

Support Center